Focused On-demand Library for snRNA-activating protein complex subunit 5

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

We utilise our cutting-edge, exclusive workflow to develop focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

O75971

UPID:

SNPC5_HUMAN

Alternative names:

Small nuclear RNA-activating complex polypeptide 5; snRNA-activating protein complex 19 kDa subunit

Alternative UPACC:

O75971; A8K7N6; Q96CF3

Background:

The snRNA-activating protein complex subunit 5, also known as Small nuclear RNA-activating complex polypeptide 5 or the snRNA-activating protein complex 19 kDa subunit, plays a crucial role in gene expression. It is a key component of the SNAPc complex, essential for the transcription of RNA polymerase II and III small-nuclear RNA genes. This protein binds to the proximal sequence element (PSE), facilitating the recruitment of TBP and BRF2 to the U6 snRNA TATA box.

Therapeutic significance:

Understanding the role of snRNA-activating protein complex subunit 5 could open doors to potential therapeutic strategies.